FMP
Oct 13, 2021 8:01 PM - Davit Kirakosyan
Ardelyx, Inc. (NASDAQ:ARDX) shares were trading around 17% lower on Wednesday as the company is still struggling to find common ground with FDA concerning tenapanor.
The company completed its Type A meeting with the FDA on Oct 1, the key takeaway from which is that the company doesn’t have a better understanding of FDA's concerns on how to define tenapanor's clinical significance and what constitutes a relevant treatment effect.
Analysts at Wedbush provided their view on the situation, mentioning that they believe FDA is unwilling to approve tenapanor and doesn't seem interested in even supplying a framework to do so. As a result, the analysts update their model to remove tenapanor credit entirely and lower their price target on the company’s shares to $1 from $2.
Sep 11, 2023 1:38 PM - Rajnish Katharotiya
Price to Earnings is one of the key metrics use to value companies using multiples. The P/E ratio and other multiples are relative valuation metrics and they cannot be looked at in isolation. One of the problems with the P/E metric is the fact that if we are in the peak of a business cycle, earni...
Sep 11, 2023 1:49 PM - Rajnish Katharotiya
Price-to-Earnings ratio is a relative valuation tool. It is used by investors to find great companies at low prices. In this post, we will build a Python script to calculate Price Earnings Ratio for comparable companies. Photo by Skitterphoto on Pexels Price Earnings Ratio and Comparable Compa...
Oct 17, 2023 3:09 PM - Davit Kirakosyan
Shares of VMware (NYSE:VMW) witnessed a sharp drop of 12% intra-day today due to rising concerns about China's review of the company's significant sale deal to Broadcom. Consequently, Broadcom's shares also saw a dip of around 4%. Even though there aren’t any apparent problems with the proposed solu...